Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Cohen Investment Advisors LLC

Cohen Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6,655.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 336,156 shares of the medical research company's stock after buying an additional 331,180 shares during the quarter. Thermo Fisher Scientific comprises approximately 4.4% of Cohen Investment Advisors LLC's investment portfolio, making the stock its 8th biggest holding. Cohen Investment Advisors LLC owned 0.09% of Thermo Fisher Scientific worth $167,271,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Norges Bank acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at $3,149,754,000. GAMMA Investing LLC boosted its stake in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Thermo Fisher Scientific by 86.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after acquiring an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC raised its position in Thermo Fisher Scientific by 1,905.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock valued at $469,889,000 after acquiring an additional 858,193 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $377,901,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.33% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TMO shares. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 24th. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Evercore ISI lowered their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Scotiabank dropped their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $604.05.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $15.89 during midday trading on Tuesday, hitting $421.35. The company's stock had a trading volume of 2,603,007 shares, compared to its average volume of 1,964,289. The company has a market cap of $159.06 billion, a P/E ratio of 24.71, a price-to-earnings-growth ratio of 2.16 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The business's 50 day simple moving average is $409.16 and its 200 day simple moving average is $481.67. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.11 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.